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A recent international workshop, organized by the authors, analyzed the obstacles facing the ambitious goal of eliminating viral 
hepatitis globally. We identified several policy areas critical to reaching elimination targets. These include providing hepatitis B birth-
dose vaccination to all infants within 24 hours of birth, preventing the transmission of blood-borne viruses through the expansion of 
national hemovigilance schemes, implementing the lessons learned from the HIV epidemic regarding safe medical practices to elim-
inate iatrogenic infection, adopting point-of-care testing to improve coverage of diagnosis, and providing free or affordable hepatitis 
C treatment to all. We introduce Egypt as a case study for rapid testing and treatment scale-up: this country offers valuable insights 
to policy makers internationally, not only regarding how hepatitis C interventions can be expeditiously scaled-up, but also as a guide 
for how to tackle the problems encountered with such ambitious testing and treatment programs.
Keywords. elimination; hepatitis care continuum; policy; viral hepatitis. 
Viral hepatitis was responsible for 1.3 million deaths globally in 
2015 and is now the seventh leading cause of mortality, rising 
from the 10th cause in 1990 [1, 2]. The full burden of disease 
encompasses not only mortality, but also reduced quality of life 
for patients (through cirrhosis and associated complications), 
financial costs of care for individuals and health care systems 
alike, and economic costs to society as a whole. Despite this 
burden, viral hepatitis has only in recent years received the 
attention it merits. Now, with a World Health Organization 
(WHO) elimination strategy published [1], the international 
community is at last focused on tackling the twin epidemics of 
hepatitis B virus (HBV) and hepatitis C virus (HCV).
At a recent conference (the first “Chronic Viral Hepatitis in 
Africa” conference, Egypt), clinicians and researchers from across 
the globe discussed the challenges of reaching WHO elimination 
targets. Considering the hepatitis care continuum (Figure 1) [3, 4], 
we identified several key areas in which progress must be made 
before elimination will be reached. We focused on those areas in 
which improvements are possible (using tools currently avail-
able) and on those aspects of treatment and care where the 
impact of changes in policy or strategy is potentially greatest. 
This viewpoint is a distillation of these discussions and is written 
with the aim of informing policy at this critical moment in the 
formation of national and international viral hepatitis programs.
HBV BIRTH-DOSE VACCINATION: CONFRONTING 
LOST OPPORTUNITIES
Scaling-up of infant vaccination has already had demonstrable 
impacts on global HBV prevalence [5]. Infant vaccination 
alone, however, does not prevent mother-to-child transmission 
(PMTCT). As the risk of chronic hepatitis B (CHB) infection is 
as high as 90% if infected perinatally [6], effective PMTCT is 
crucial to reducing incidence.
A key component of a comprehensive PMTCT strategy is 
birth-dose vaccination. Modeling studies have suggested that 
an 80% global scale-up of birth-dose vaccination plus infant 
vaccination, compared with scaling-up of infant vaccination 
alone, could avert 18.7 million new chronic infections over the 
next 15 years, highlighting its importance as a PMTCT tool [7]. 
Monovalent HBV vaccine is inexpensive (US$0.20 per dose), 
and birth-dose vaccination is likely to be cost-effective [8].
Despite such evidence, global HBV birth-dose vaccine cover-
age remains low, at 39% [9]. Moreover, vaccines are often adminis-
tered beyond 24 hours of birth [10], when they are less effective in 
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PMTCT [11, 12]. There are several reasons for this low coverage: the 
monovalent vaccine is not funded by agencies like GAVI, as the cost 
of the vaccine falls below their funding threshold [13]; there are sig-
nificant costs for vaccine delivery [14]; cultural factors may reduce 
access to health care by women in the postpartum period [15]; and 
hepatitis B interventions are rarely a public health priority [16], with 
only 9 countries in sub-Saharan Africa, for example, incorporating 
birth-dose vaccination into their national policies by 2015 [10, 17].
Innovative approaches exist to improve timely birth-dose 
vaccination administration, including increasing the number 
of health staff–attended births [18], ensuring coordination 
between immunization and maternal health services [19], 
expanding vaccine management systems [19], using prefilled 
injectable vaccines for home births [20], promoting awareness 
of the need for timely HBV vaccination [21], and simplifying 
the supply chain by, for example, using heat-sensitive labels to 
allow storage of vaccine outside the cold chain [22, 23].
A substantial scale-up in birth-dose vaccination coverage is 
pivotal to reaching WHO 2030 elimination targets [1]. This is 
long overdue, and acceleration of efforts requires a combination 
of political engagement by governments, financial commit-
ment, and strategic planning to help countries reach these goals.
IATROGENIC TRANSMISSION: A COST-EFFECTIVE 
APPROACH TO CURBING TRANSMISSION
Blood and injection safety are fundamental to national viral hep-
atitis programs [1]. In Africa, for example, the risk of acquiring 
HCV from blood is 2.5 per 1000 units transfused, compared with 
1 per 2–3 million units in high-income countries [24]. In add-
ition, the reuse of injection equipment, inadequate sterilization 
procedures, lack of universal precautions, sharps injuries, and 
inadequate medical waste management systems all contribute 
to the burden of viral hepatitis. To reach WHO targets by 2030, 
all blood donations should be screened for HIV, HCV, HBV, 
and syphilis in a quality-assured manner, and 90% of injections 
should be administered using a safety-engineered device [25].
There are several options for reducing risk of transfu-
sion-transmissible infections (TTIs). Centralized blood trans-
fusion services targeting low-risk, regular, voluntary blood 
donors should be developed and integrated into health care sys-
tems [26]. Although more expensive than replacement donor 
systems [27], voluntary blood donors represent a safer, more 
sustainable approach [28] and should contribute at least 80% of 
all donations to transfusion services [29]. All donations should 
be screened for TTIs, with external quality assurance, using 
highly sensitive and specific assays [30, 31]. National hemovigi-
lance systems supported by local transfusion committees enable 
ongoing surveillance for transfusion-related complications [32], 
but in low- and middle-income countries (LMICs), only 28% 
operate hemovigilance systems [33]. Blood safety programs 
can be cost-effective [34], but cost-effectiveness varies, and 
this should inform program design: adding antigen-antibody 
combination tests to reduce the serologically negative window 
period can be cost-effective [35], whereas TTI predonation 
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Figure 1. Overview of the WHO care continuum for viral hepatitis and the associated challenges encountered when aiming toward WHO elimination targets, adapted 
fromn Zhou et al. [3]. Populations within the care continuum for viral hepatitis are as defined within the Global Health Sector Strategy on Viral Hepatitis [4]. Abbreviations: 
HBV = hepatitis B virus; HCV = hepatitis C virus; WHO = World Health Organization.
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screening using rapid diagnostic tests (RDTs) is not considered 
to be cost-effective [36].
Improving injection safety is also key to reducing iatrogenic 
transmission: in 2010, approximately 1.7 million new cases of HBV 
and up to 315 000 new cases of HCV were attributable to unsafe 
injections [37]. Such infections can be avoided through the use of 
safety-engineered devices that protect health care workers from 
hazardous occupational exposures to bodily fluids [38], needle/
sharps hygiene and safe disposal, and a ban on needle reuse [39]. 
Such measures must be delivered alongside education of health 
care workers in universal precautions and safe waste management 
systems. National policies for safe and appropriate use of injec-
tions are, furthermore, highly cost-effective [40]. Global bodies 
must take the lead in promoting and financing blood screening 
and injection safety initiatives to ensure that these cheap and ef-
fective interventions are implemented worldwide.
DIAGNOSTICS FOR HCV: TACKLING THE 
BOTTLENECK
The advent of highly efficacious direct-acting antiviral (DAA) 
treatment has revolutionized the therapeutic landscape for 
chronic HCV infection, but less attention has been paid to screen-
ing and diagnosis. Given the nature of the infection, asymptom-
atic HCV-infected individuals are unlikely to seek health care 
[41]. Consequently, WHO targets of 90% of active infections 
diagnosed by 2030 [1] are aspirational, outstripping the diagnosis 
coverage achieved even in those countries that have been most 
successful in identifying infected individuals, such as France, 
Australia, and Sweden [42]. Currently, a 2-step process for diag-
nosing active HCV infection is usually required: a serological test 
to screen for exposure, followed by an HCV RNA nucleic acid 
test (NAT) to confirm viremia [43]. This 2-step process inevitably 
leads to patient loss to follow-up (LTFU) [44–46]. Furthermore, 
in LMIC, NAT is economically challenging, and the specialized 
laboratory staff and equipment are often not available [47, 48].
Alternatively, serum HCV core antigen quantification 
(HCVcAg) can be used as a surrogate marker for HCV viremia. 
Testing HCVcAg is a relatively low cost (as low as US$10 per 
sample [49]), fully automated, and a commercially available assay 
that can be performed on the Abbott ARCHITECT platform, 
making it an attractive test for resource-limited settings [49, 50]. 
Employing HCVcAg testing while still dependent on a central-
ized testing facility can “uncouple” the sample collection from the 
testing site through the use of dried blood spot (DBS) samples 
[51, 52]: While whole blood and plasma samples require prompt 
transport to the laboratory or refrigeration, DBS samples can be 
stored at room temperature for several weeks [53]. The robust-
ness of this sample storage technique makes it ideal for decen-
tralizing testing, which is attractive for resource-limited settings 
[43]. Though testing DBS samples for HCVcAg has been shown 
to have reduced sensitivity compared with using serum samples 
[52, 54], the low cost and uncoupling of sample and testing site 
suggest a role for DBS testing in marginalized populations un-
likely to present at centralized testing facilities [54].
The development and validation of RDTs has become a 
research priority. The WHO has prequalified 2 HCV RDTs: 
SDBioline (SDBioline, Gyeonggi-do, Republic of Korea) and 
Oraquick (OraSure Technologies Inc., Bethlehem, PA) [55, 56], 
an oral fluid-based point-of-care (POC) test with a comparable 
performance to third-generation enzyme immunoassays (EIAs) 
[57]. POC testing has been shown to improve HIV linkage to 
care in LMIC and to be cost-effective [58-60, S61]. Combination 
RDTs for HIV, HBV, and HCV have also been shown to increase 
uptake and receipt of results relative to laboratory testing [S62].
Finally, the adoption of pangenotypic DAA regimens may 
eliminate the requirement for genotype testing entirely [53]. All 
such developments can simplify and strengthen the diagnosis 
and treatment cascade, removing potential causes of LTFU, 
and will be crucial in reaching diagnosis and treatment targets. 
Active implementation of affordable POC testing at the primary 
care level will be essential to upscale identification and linkage 
to care of infected individuals.
PROVIDING CARE: ACCESSING HARD-TO-REACH 
HCV-INFECTED POPULATIONS
In most countries, anti-HCV prevalence is well below 10% in the 
general population [S63] but significantly greater in high-risk pop-
ulations. The most studied population is PWID, in which anti-HCV 
prevalence can exceed 90% [S64], but men who have sex with men 
(MSM) and other recreational drug users are increasingly being 
recognized as significant at-risk populations [S65, S66]. Such popu-
lations are often difficult to reach for a variety of reasons, including 
stigma and the possibility of prosecution [S67, S68]. Programs spe-
cifically designed to address epidemics within these populations are 
critical to the success of disease burden reduction efforts.
Qualitative [S69,  S70] and quantitative [S71–S73] research 
has shown that PWID are interested in engaging with health care 
services for HCV testing and treatment; there is clear evidence of 
successful treatment outcomes in this group [S74], yet treatment 
in PWID remains suboptimal [S75,S76]. Health care provider 
concerns can act as barriers to HCV treatment. Such concerns 
may include the presence of comorbidities, the belief that there 
will be adherence issues, and difficulties managing side effects 
[S77]. From a patient perspective, there are several factors that 
may reduce the likelihood of accessing HCV treatment, includ-
ing negative experiences within health care systems [S78, S79], 
low literacy rates [S80,  S81], inadequate communication with 
health care providers regarding the nature of the disease and 
treatment options [S79], and social factors such as discrimin-
ation, the threat of stigmatization, and criminalization [S81].
Reviews of treatment models in high-income countries suggest 
that effective approaches to improving rates of HCV diagnosis 
and treatment integrate HCV services into addiction care units 
[S82]. Focusing on treatment of addiction [S83] and encouraging 
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positive feedback between health care staff and PWID [S84] 
improve outcomes. Such multidisciplinary approaches reduce 
noncompliance even among homeless or active illicit drug users 
[S85]. Similar approaches can be utilized in general practitioner 
services; a study in the United Kingdom demonstrated how spe-
cialist nurses seconded to primary care facilities can offer screen-
ing to at-risk individuals, considerably improving HCV detection 
[S86]. An alternative approach may be treatment as prevention: 
Modeling suggests that it may be effective at curbing transmis-
sion in both PWID [S87] and MSM [S88].
In LMIC, many patients, in addition to those discussed above, 
are hard to reach through lack of health care services. In such 
scenarios, HCV screening could be integrated into existing 
care delivery models for HIV and tuberculosis (TB) [S89, S90]. 
Success of HIV treatment roll-out offers valuable lessons [43]: 
Community-based testing improves uptake among high–CD4 
count individuals compared with facility-based approaches 
[S91], and we propose that the impressive improvements in HIV 
case finding could be replicated for HCV using similar methods.
TREATING HBV INFECTION: SETTING GLOBAL 
STANDARDS TO SIMPLIFY CARE
Achieving ambitious WHO testing and treatment targets for 
HBV requires careful consideration of the challenges of scale-up; 
discussion should focus on simplified models of care and meth-
ods of wide-scale testing and treatment, particularly in LMICs.
Treatment for CHB targets individuals with, or at risk for, 
advanced liver disease, and aims to suppress virus replication, halt 
disease progression, prevent complications, and avert HBV-related 
deaths [S92–S94]. Several antiviral agents approved for the treat-
ment of CHB are available in developed countries, with regional 
guidelines outlining a continuum of care and recommendations on 
who to treat, how to treat, and when to stop treatment [S95–S96]. 
These documents, while based on evidence of drug efficacy and 
benefits of treatment, are not adapted for use in countries where 
CHB is endemic and HBV-related mortality is highest [2]. WHO 
guidelines for the prevention and treatment of CHB attempt to 
address this unmet need [S94]. Tenofovir is the recommended 
antiviral in resource-limited settings, with entecavir recommended 
in children aged 2–11 years. The guidelines encourage the use of 
clinical parameters (clinical diagnosis of cirrhosis) and/or nonin-
vasive tests (APRI score > 2) to assess severity of liver disease.
WHO guidelines suggest that treatment should be targeted at 
those with the highest risk of disease progression, based on the 
detection of persistently raised alanine aminotransferase (ALT), 
and HBV DNA levels greater than 20 000 IU/mL in those older 
than age 30 years [S94]. All cirrhotics should be treated regard-
less of ALT levels, HBeAg status, or HBV DNA levels. The sim-
plicity of administration of these antivirals, their tolerability 
and safety profiles, and their high barrier to resistance make 
them ideal for long-term use in regions where close monitoring 
and management of adverse effects may not be feasible.
While there is consensus that cirrhotics require lifelong treat-
ment, the safety of stopping therapy in noncirrhotic patients 
remains less clear. Most international guidelines recommend dis-
continuation of therapy for noncirrhotic HBeAg-positive indi-
viduals who show evidence of HBeAg loss and seroconversion 
to antibody to HBeAg (anti-HBe), undetectable HBV DNA, and 
who complete at least 12 months of consolidation therapy [S94]. 
Discontinuation is only recommended when ALT and HBV 
DNA levels can be monitored, as a high proportion relapse after 
stopping treatment [S94,  S97], placing an additional financial 
strain on health care systems. Antiviral therapy can be stopped in 
noncirrhotic HBeAg-negative individuals at least 12 months fol-
lowing loss of HBsAg and achieving anti-HBs status [S98]. This 
needs to be accompanied by sustained virological suppression and 
normalization of ALT, with off-treatment monitoring for relapse. 
With only a small proportion of patients achieving HBsAg loss, 
and with the need for regular monitoring for reactivation and 
flares after cessation of antiviral therapy in both HBeAg-positive 
and -negative individuals, we believe it is advisable at present to 
treat all patients indefinitely [S98]. The additional financial bur-
den that such lifelong treatment imposes, however, as well as 
challenges to maintaining people in the cascade of care, must be 
acknowledged when adopting this approach.
An additional complication is access to treatment in LMICs: 
despite generic tenofovir costing less than US$50 per annum 
and being accessible to HIV-HBV co-infected individuals as 
part of antiretroviral therapy, many HBV-monoinfected indi-
viduals cannot access antiviral therapy or have to pay out of 
pocket. National health care systems need to ensure funded, 
sustainable access to antiviral therapy for HBV-mono-infected 
individuals, implemented in concert with diagnosis scale-up 
strategies.
Treatment programs need to be accompanied by wide-scale 
HBV testing, particularly in LMICs, where screening rates are 
low. Community-based testing and treatment for chronic HBV 
infection has been shown to be feasible: In The Gambia, the 
Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) 
study showed that POC HBV tests perform well in African com-
munity settings [S99], and subsequently demonstrated that com-
munity-based screening could achieve high coverage and good 
linkage to care [S100] while remaining cost-effective [S101].
THE COST OF DIRECT-ACTING ANTIVIRALS FOR 
HCV: HOW PROGRESS CAN BE MADE
A 12-week DAA course costs in excess of US$70  000 in the 
United States today [S102]. With an estimated 71 million active 
HCV infections globally [1], such prices render any program 
aimed at global HCV elimination unrealistic. In 2016, the WHO 
reported a range of approaches adopted by several countries to 
demonstrate how barriers to treatment can be overcome [S103].
In LMICs where patents have not been filed or remain under 
examination, a market for low-cost, generic versions of patented 
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drugs can be created. Sofosbuvir is not patented in Egypt, and a 
28-day supply currently costs under US$30 [S104]. India has used 
this approach to facilitate production of generics, but a recent 
decision to grant a patent to Gilead for Sofosbuvir may damage 
India’s role as an HCV generics producer [S105]. Pharmaceutical 
companies have, in places, awarded voluntary license agreements 
to permit local companies to produce generics. As of August 2015, 
Gilead had 11 such agreements with Indian companies [S106]. 
Additionally, the originator company of Daclatasvir has signed an 
agreement with the Medicines Patent Pool to enable sublicensing 
to multiple generic manufacturers in 112 LMICs [S103]. Many 
middle-income countries are viewed as having market potential 
and are excluded from these agreements, including China, Brazil, 
and Thailand [S106]. More generally, complexities of volun-
tary licensing fragment the market, ensuring that pricing power 
remains in the hands of pharmaceutical companies [S107]. This 
problem can be circumvented by development of new therapies: 
The Drugs for Neglected Diseases Initiative (DNDi) has obtained 
the license for a new HCV DAA, ravidasvir. This has allowed it to 
begin production of the drug through an Egyptian firm, Pharco 
Pharmaceuticals, without the need to maximize profit [S108].
High-income countries can bulk purchase to reduce costs; 
no country has attempted this more ambitiously than Australia. 
The government agreed to a AU$1 billion (US$0.73 billion) 
program to treat 62 000 individuals, corresponding to per-treat-
ment costs of around US$12 000 [S109]. The true novelty of the 
Australian approach is that if expenditure exceeds up-front cost, 
the price of drugs decreases, potentially to 0 [S109]. Australia 
has, in effect, created a subscription system, paying a fixed 
amount and treating as many Australians as it can.
What ultimately unites these approaches is their customized 
nature; some countries have had success in reducing prices, but 
others risk being left behind. A unified approach must be taken 
to ensure that high-quality, low-cost drugs are available regard-
less of location. Pooled procurement is one method for achieving 
this, an approach pioneered by the Global Fund to tackle the HIV, 
malaria, and TB epidemics [S110], and attempts are underway to 
apply this approach to viral hepatitis [S111]. Such schemes could 
be transformative; however, they will rely on capital and political 
will to achieve the scale required for the program to be a success.
Egypt as a Case Study
Egypt serves as a model for HCV diagnosis and treatment 
scale-up [S104,  S112]. This country, with the world’s highest 
HCV prevalence, has increased HCV treatment numbers to the 
hundreds of thousands [S103] and intends to treat 5 million 
patients by 2030 [S104]. It has achieved this by slashing HCV 
treatment costs and empowering dozens of diagnostic facilities. 
Furthermore, by simplifying the diagnostic process through 
implementing the first universal test and treat strategy, it has 
reduced the time from initial diagnosis to treatment to as little 
as one week in some centers [104]. Egypt offers an invaluable 
example to policy makers, not only as an exemplar of how viral 
hepatitis interventions can be scaled-up quickly and intensively, 
but also as a guide for how to tackle the problems that may be 
faced with such ambitious interventions.
Recommendations
Egypt demonstrates what can be accomplished with regards to 
HCV diagnosis and treatment, given sufficient political will, 
state coordination, and investment. Across the world, efforts 
to address viral hepatitis, both HBV and HCV, should focus 
on providing universal HBV birth-dose vaccination within 24 
hours of birth, establishing hemovigilance schemes to prevent 
transmission of blood-borne viruses, providing nonreusable 
syringes and educating health staff in injection safety, adopt-
ing new diagnostic technologies to expand access to screen-
ing, specializing intervention efforts for vulnerable high-risk 
groups to reduce transmission where it is highest, treating all 
HBV-infected patients indefinitely to minimize potential harm 
caused by discontinuation, and collaborating across the contin-
ent to drive down HCV drug costs to ensure that, once treat-
ment has been accessed, it is affordable.
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